pirenzepine has been researched along with Psychotic Disorders in 192 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Psychotic Disorders: Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The subjects were 45 inpatients with DSM-IV schizophrenia or schizoaffective disorder who failed to respond to treatment during a 14-week double-blind trial comparing clozapine, olanzapine, risperidone, and haloperidol." | 9.10 | Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. ( Chakos, M; Citrome, L; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2002) |
| "A multicenter, randomized, international, 2-year study comparing the risk for suicidal behavior in patients treated with clozapine vs olanzapine was conducted in 980 patients with schizophrenia or schizoaffective disorder, 26." | 9.10 | Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). ( Alphs, L; Altamura, AC; Anand, R; Bertoldi, A; Bourgeois, M; Chouinard, G; Green, AI; Islam, MZ; Kane, J; Krishnan, R; Lindenmayer, JP; Meltzer, HY; Potkin, S, 2003) |
| "The aim of the present study was to evaluate the objective and subjective efficacy as well as tolerability of olanzapine in acute treatment of schizophrenia spectrum disorders under naturalistic non-selective conditions." | 9.10 | Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders. ( Holzbach, R; Krausz, M; Lambert, M; Moritz, S; Naber, D; Postel, N, 2003) |
| "To examine the effects of risperidone and olanzapine on cognitive functioning in elderly patients with schizophrenia or schizoaffective disorder." | 9.10 | Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. ( Gharabawi, G; Harvey, PD; Mao, L; Napolitano, JA, 2003) |
| "To determine whether patients with treatment-resistant schizophrenia or schizoaffective disorder would respond when switched to olanzapine and whether they could maintain their response on this atypical antipsychotic." | 9.10 | Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up. ( Karagianis, JL; LeDrew, KK; Walker, DJ, 2003) |
| "To compare the effects of risperidone and olanzapine on cognition in elderly patients with dementia and psychosis, and to compare the side effects of these drugs." | 9.10 | Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis. ( Arndt, S; Ekstam-Smith, K; Ellingrod, VL; Kutscher, E; Schultz, SK; Turvey, C, 2002) |
| "The authors compared the efficacy and safety of three atypical antipsychotics (clozapine, olanzapine, and risperidone) with one another and with haloperidol in the treatment of patients with chronic schizophrenia or schizoaffective disorder." | 9.10 | Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2002) |
| "4 years) with DSM-IV schizophrenia or related disorders (N = 113) who were treated with olanzapine or risperidone." | 9.10 | Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. ( Beuk, N; de Haan, L; Dingemans, P; Hoogenboom, B; Linszen, D, 2002) |
| "Newer antipsychotic drugs have shown promise in ameliorating neurocognitive deficits in patients with schizophrenia, but few studies have compared newer antipsychotic drugs with both clozapine and conventional agents, particularly in patients who have had suboptimal response to prior treatments." | 9.10 | Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. ( Bilder, RM; Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Goldman, RS; Hoptman, M; Horowitz, TL; Kunz, M; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J, 2002) |
| "Olanzapine's structural similarities to clozapine and the results of premarketing clinical trials suggested potential usefulness in treating patients with treatment-refractory psychoses." | 9.09 | An open trial of olanzapine in patients with treatment-refractory psychoses. ( Mossman, D; Sanders, RD, 1999) |
| "Weight change and the weight-related health factors of nonfasting serum glucose, serum cholesterol, and diastolic blood pressure levels were analyzed in patients with DSM-III-R schizophrenia and related disorders who received treatment with olanzapine for up to 3 years, and comparisons were made to patients treated with haloperidol." | 9.09 | Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. ( Basson, BR; Gilmore, JA; Kinon, BJ; Tollefson, GD, 2001) |
| " Amantadine (100-300 mg/day) was started in 12 patients having a mean weight gain of 7." | 9.09 | Effect of amantadine on weight gain during olanzapine treatment. ( Deberdt, W; Floris, M; Lejeune, J, 2001) |
| "Subjects (N=377) who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomly assigned to receive 2-6 mg/day of risperidone (mean modal dose=4." | 9.09 | A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. ( Conley, RR; Mahmoud, R, 2001) |
| "A total of 157 inpatients with schizophrenia or schizoaffective disorder and a history of suboptimal treatment response were randomly assigned to receive clozapine, olanzapine, risperidone, or haloperidol in a double-blind 14-week trial." | 9.09 | Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J, 2001) |
| "To determine the clinical effects and safety of olanzapine as compared with placebo, typical and other atypical antipsychotic drugs for schizophrenia and schizophreniform psychoses." | 8.82 | Olanzapine for schizophrenia. ( Dardennes, RM; Duggan, L; El-Dosoky, A; Fenton, M; Indran, S, 2003) |
| "The frequency of neuroleptic malignant syndrome (NMS) after clozapine or olanzapine is low and often of non-serious nature." | 8.82 | [Life threatening neuroleptic malignant syndrome due to olanzapine]. ( Becker, T; Kopf, A; Köster, J; Krömker, H; Schulz, A, 2003) |
| "To evaluate the efficacy and safety of olanzapine for the treatment of psychotic and behavioral disturbances in Alzheimer disease." | 8.82 | Olanzapine for psychotic and behavioral disturbances in Alzheimer disease. ( Schatz, RA, 2003) |
| "To determine the clinical effects and safety of olanzapine as compared with placebo, typical and other atypical antipsychotic drugs for schizophrenia and schizophreniform psychoses." | 8.80 | Olanzapine for schizophrenia. ( Dardennes, RM; Duggan, L; El-Dosoky, A; Fenton, M; Indran, S, 2000) |
| "Olanzapine is a thienobenzodiazepine derivative which displays efficacy in patients with schizophrenia and related psychoses." | 8.79 | Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. ( Fulton, B; Goa, KL, 1997) |
| "The increasing use of olanzapine for treating adolescent patients has brought with it greater awareness of the recognized side effects of this medication, especially weight gain." | 7.72 | Hyperglycemia from olanzapine treatment in adolescents. ( Bloch, Y; Gothelf, D; Levkovitz, Y; Mendlovic, S; Ratzoni, G; Vardi, O, 2003) |
| "These data demonstrate that, in older patients with schizophrenia and related psychotic disorders, risperidone and olanzapine have approximately equal efficacy in controlling positive symptoms." | 7.72 | Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. ( Breier, A; Feldman, PD; Kaiser, CJ; Kennedy, JS; Sutton, VK; Tollefson, GD; Tran, PV; Zhang, F, 2003) |
| " We report a 48 years old male drinker and addicted to cocaine, that after two months of Olanzapine use, developed a severe diabetes mellitus with fasting blood glucose values reaching 514 mg/dl." | 7.71 | [Diabetes mellitus induced by olanzapine. A case report]. ( Arancibia, P; Bravo, V; Rojas, P; Varela, S, 2001) |
| "Three studies compared olanzapine and haloperidol given orally in maintenance therapy for schizophrenia and related psychoses." | 7.70 | Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. ( Beasley, CM; Dellva, MA; Tollefson, GD; Tran, PV; Wentley, AL, 1998) |
| "The aim of the present paper is to report a case of Neuroleptic Malignant Syndrome (NMS) occurring 2 days after olanzapine was added to the treatment regimen of an elderly patient with Schizoaffective Disorder." | 7.70 | Neuroleptic malignant syndrome associated with olanzapine. ( Bruxner, G; Johnson, V, 1998) |
| "Fourteen patients on treatment with olanzapine (all meeting DSM-IV criteria for schizophrenia or related psychoses) were studied." | 7.70 | Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. ( Brismar, KE; Hulting, AL; Melkersson, KI, 2000) |
| "Olanzapine is a novel antipsychotic effective in reducing positive and negative symptoms of schizophrenia and with a safe side-effect profile." | 6.69 | Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. ( Brenner, R; Concepcion, NM; Florita, CD; Kaur, A; Madhusoodanan, S; Menon, G; Nunez, G; Reddy, H; Suresh, P, 2000) |
| " The manuscript describes the pharmacology, efficacy and tolerability studies, adverse effects and dosing considerations in the elderly." | 6.41 | Use of olanzapine for elderly patients with psychotic disorders: a review. ( Bogunovic, O; Brenner, R; Gupta, S; Madhusoodanan, S; Sinha, S, 2001) |
| "Twenty-one patients with Parkinson's disease and psychosis were included in an open-label 8-week trial of olanzapine." | 5.30 | Olanzapine for psychosis in patients with Parkinson's disease with and without dementia. ( Aarsland, D; Larsen, JP; Lim, NG; Tandberg, E, 1999) |
| "In a prospective, single-blinded, naturalistic study, a cohort of subjects (n=150) with schizophrenia or schizo-affective disorder (DSM-IV) were switched from conventional neuroleptic drugs to either risperidone (n=50), olanzepine (n=50) or quetiapine (n=50), and monitored for a period of 2 to 6 years." | 5.10 | Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. ( Awad, A; Cernovsky, Z; Cortese, L; Kotteda, V; Owyeumi, L; Voruganti, L; Zirul, S, 2002) |
| "The subjects were 45 inpatients with DSM-IV schizophrenia or schizoaffective disorder who failed to respond to treatment during a 14-week double-blind trial comparing clozapine, olanzapine, risperidone, and haloperidol." | 5.10 | Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. ( Chakos, M; Citrome, L; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2002) |
| "A multicenter, randomized, international, 2-year study comparing the risk for suicidal behavior in patients treated with clozapine vs olanzapine was conducted in 980 patients with schizophrenia or schizoaffective disorder, 26." | 5.10 | Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). ( Alphs, L; Altamura, AC; Anand, R; Bertoldi, A; Bourgeois, M; Chouinard, G; Green, AI; Islam, MZ; Kane, J; Krishnan, R; Lindenmayer, JP; Meltzer, HY; Potkin, S, 2003) |
| " The authors' goal was to assess the effects of clozapine, olanzapine, risperidone, and haloperidol on glucose and cholesterol levels in hospitalized patients with schizophrenia or schizoaffective disorder during a randomized double-blind 14-week trial." | 5.10 | Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2003) |
| "The aim of the present study was to evaluate the objective and subjective efficacy as well as tolerability of olanzapine in acute treatment of schizophrenia spectrum disorders under naturalistic non-selective conditions." | 5.10 | Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders. ( Holzbach, R; Krausz, M; Lambert, M; Moritz, S; Naber, D; Postel, N, 2003) |
| "To examine the effects of risperidone and olanzapine on cognitive functioning in elderly patients with schizophrenia or schizoaffective disorder." | 5.10 | Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. ( Gharabawi, G; Harvey, PD; Mao, L; Napolitano, JA, 2003) |
| "To determine whether patients with treatment-resistant schizophrenia or schizoaffective disorder would respond when switched to olanzapine and whether they could maintain their response on this atypical antipsychotic." | 5.10 | Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up. ( Karagianis, JL; LeDrew, KK; Walker, DJ, 2003) |
| "To compare the effects of risperidone and olanzapine on cognition in elderly patients with dementia and psychosis, and to compare the side effects of these drugs." | 5.10 | Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis. ( Arndt, S; Ekstam-Smith, K; Ellingrod, VL; Kutscher, E; Schultz, SK; Turvey, C, 2002) |
| "The authors compared the efficacy and safety of three atypical antipsychotics (clozapine, olanzapine, and risperidone) with one another and with haloperidol in the treatment of patients with chronic schizophrenia or schizoaffective disorder." | 5.10 | Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2002) |
| "4 years) with DSM-IV schizophrenia or related disorders (N = 113) who were treated with olanzapine or risperidone." | 5.10 | Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. ( Beuk, N; de Haan, L; Dingemans, P; Hoogenboom, B; Linszen, D, 2002) |
| "Newer antipsychotic drugs have shown promise in ameliorating neurocognitive deficits in patients with schizophrenia, but few studies have compared newer antipsychotic drugs with both clozapine and conventional agents, particularly in patients who have had suboptimal response to prior treatments." | 5.10 | Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. ( Bilder, RM; Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Goldman, RS; Hoptman, M; Horowitz, TL; Kunz, M; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J, 2002) |
| "Olanzapine's structural similarities to clozapine and the results of premarketing clinical trials suggested potential usefulness in treating patients with treatment-refractory psychoses." | 5.09 | An open trial of olanzapine in patients with treatment-refractory psychoses. ( Mossman, D; Sanders, RD, 1999) |
| "Two hundred nine outpatients with a DSM-IV diagnosis of schizophrenia or schizo-affective disorder who were clinically stable while being treated with a conventional antipsychotic drug or risperidone were openly randomly assigned to either abrupt or gradual discontinuation of their prior antipsychotic drug." | 5.09 | Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. ( Basson, BR; Gilmore, JA; Kinon, BJ; Malcolm, S; Stauffer, VL, 2000) |
| "Clozapine is an atypical antipsychotic indicated for the management of severely ill patients with schizophrenia who have failed to respond adequately to standard drug treatment." | 5.09 | Switching clozapine responders to olanzapine. ( Hilligoss, NM; Johnson, CG; Littrell, KH; Littrell, SH; Peabody, CD, 2000) |
| " This article compares the effects of olanzapine and placebo in the emergence of hallucinations or delusions in AD patients with symptoms of agitation/aggression but little or no psychotic symptomatology at baseline." | 5.09 | The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. ( Breier, A; Clark, WS; Feldman, PD; Street, JS, 2001) |
| "Weight change and the weight-related health factors of nonfasting serum glucose, serum cholesterol, and diastolic blood pressure levels were analyzed in patients with DSM-III-R schizophrenia and related disorders who received treatment with olanzapine for up to 3 years, and comparisons were made to patients treated with haloperidol." | 5.09 | Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. ( Basson, BR; Gilmore, JA; Kinon, BJ; Tollefson, GD, 2001) |
| " Amantadine (100-300 mg/day) was started in 12 patients having a mean weight gain of 7." | 5.09 | Effect of amantadine on weight gain during olanzapine treatment. ( Deberdt, W; Floris, M; Lejeune, J, 2001) |
| "Subjects (N=377) who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomly assigned to receive 2-6 mg/day of risperidone (mean modal dose=4." | 5.09 | A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. ( Conley, RR; Mahmoud, R, 2001) |
| ", who received at least 6 weeks of add-on olanzapine treatment for psychotic mood disorders (schizoaffective disorders [bipolar and depressive type], bipolar disorders [I, II, and NOS], and major depressive disorder)." | 5.09 | Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study. ( Grace, JJ; Narendran, R; Pato, MT; Pristach, CA; Valenti, AM; Young, CM, 2001) |
| "A total of 157 inpatients with schizophrenia or schizoaffective disorder and a history of suboptimal treatment response were randomly assigned to receive clozapine, olanzapine, risperidone, or haloperidol in a double-blind 14-week trial." | 5.09 | Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J, 2001) |
| "Data were analyzed from three actively controlled and blind long-term responder studies of subjects meeting DSM-III-R criteria for schizophrenia, schizophreniform disorder, or schizoaffective disorder treated with olanzapine (N = 707, up to 20 mg/day, 237 median days of exposure) or haloperidol (N = 197, up to 20 mg/day, 203 median days of exposure) who did not have evidence of tardive dyskinesia at baseline." | 5.08 | Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. ( Beasley, CM; Potvin, JH; Tamura, RN; Tollefson, GD; Tran, PV, 1997) |
| "To determine the clinical effects and safety of olanzapine as compared with placebo, typical and other atypical antipsychotic drugs for schizophrenia and schizophreniform psychoses." | 4.82 | Olanzapine for schizophrenia. ( Dardennes, RM; Duggan, L; El-Dosoky, A; Fenton, M; Indran, S, 2003) |
| "The frequency of neuroleptic malignant syndrome (NMS) after clozapine or olanzapine is low and often of non-serious nature." | 4.82 | [Life threatening neuroleptic malignant syndrome due to olanzapine]. ( Becker, T; Kopf, A; Köster, J; Krömker, H; Schulz, A, 2003) |
| "To evaluate the efficacy and safety of olanzapine for the treatment of psychotic and behavioral disturbances in Alzheimer disease." | 4.82 | Olanzapine for psychotic and behavioral disturbances in Alzheimer disease. ( Schatz, RA, 2003) |
| " The present article reviews important differences among antipsychotic drugs in the potential for, and occurrence of, serious adverse cardiac outcomes and suggests that olanzapine, as therapeutically administered to patients with schizophrenia and related psychoses, does not contribute significantly to a QTc prolongation that could result in potentially fatal ventricular arrhythmias." | 4.81 | Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. ( Beasley, CM; Czekalla, J; Kollack-Walker, S, 2001) |
| "A computerized search, using the MEDLINE database (1966-summer 2000), located cases of priapism associated with most conventional antipsychotics as well as with clozapine, risperidone, and olanzapine." | 4.81 | Priapism associated with conventional and atypical antipsychotic medications: a review. ( Compton, MT; Miller, AH, 2001) |
| "To determine the clinical effects and safety of olanzapine as compared with placebo, typical and other atypical antipsychotic drugs for schizophrenia and schizophreniform psychoses." | 4.80 | Olanzapine for schizophrenia. ( Dardennes, RM; Duggan, L; El-Dosoky, A; Fenton, M; Indran, S, 2000) |
| " Compared with risperidone, olanzapine causes greater increases in weight gain and body mass index but less hyperprolactinemia." | 4.80 | Adverse events related to olanzapine. ( Conley, RR; Meltzer, HY, 2000) |
| "Olanzapine is a thienobenzodiazepine derivative which displays efficacy in patients with schizophrenia and related psychoses." | 4.79 | Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. ( Fulton, B; Goa, KL, 1997) |
| " This article will describe the potential use of the atypical antipsychotics, especially olanzapine, for affective mood disturbances in schizophrenia, psychotic depression and mania, first-break schizophrenia, comorbid schizophrenia and substance abuse disorders, dementia in the elderly and those with late-onset schizophrenia, and behavioral problems in patients with mental retardation or developmental delays." | 4.79 | Olanzapine and the new generation of antipsychotic agents: patterns of use. ( Glazer, WM, 1997) |
| "The unprecedented level of activity in the development of new antipsychotic medications can be traced to the 1989 approval of clozapine by the US Food and Drug Administration for treatment of refractory schizophrenia." | 4.79 | New antipsychotic medications: strategies for evaluation and selected findings. ( Schooler, NR, 1997) |
| " Risperidone Olanzapine Drug Outcomes Studies in Schizophrenia (RODOS-UK) program consisted of a retrospective review of medical notes and prescription charts for 501 patients with schizophrenia or schizoaffective disorder who had been admitted to the hospital for the treatment of psychosis." | 3.72 | Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. ( Libretto, SE; Taylor, DM; Wright, T, 2003) |
| "The increasing use of olanzapine for treating adolescent patients has brought with it greater awareness of the recognized side effects of this medication, especially weight gain." | 3.72 | Hyperglycemia from olanzapine treatment in adolescents. ( Bloch, Y; Gothelf, D; Levkovitz, Y; Mendlovic, S; Ratzoni, G; Vardi, O, 2003) |
| "These data demonstrate that, in older patients with schizophrenia and related psychotic disorders, risperidone and olanzapine have approximately equal efficacy in controlling positive symptoms." | 3.72 | Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. ( Breier, A; Feldman, PD; Kaiser, CJ; Kennedy, JS; Sutton, VK; Tollefson, GD; Tran, PV; Zhang, F, 2003) |
| "Ten of 20 stable patients with schizophrenia or schizoaffective disorder who were treated with olanzapine for at least 4 weeks had the opportunity to receive access to a Young Men's Christian Association (YMCA) fitness facility, based on random allocation." | 3.72 | Pilot study: access to fitness facility and exercise levels in olanzapine-treated patients. ( Archie, S; Hobbs, H; McNiven, J; Osborne, S; Wilson, JH, 2003) |
| "Twenty-four patients taking daily doses of olanzapine of 20, 25, 30, and 40 mg for DSM-IV schizophrenia or schizoaffective disorder had serum prolactin levels measured." | 3.72 | High-dose olanzapine and prolactin levels. ( Baksh, A; Karagianis, JL, 2003) |
| "Patients with a Diagnostic and Statistical Manual of Mental Disorders (third edition, revised) diagnosis of schizophrenia or psychotic disorder not otherwise specified with onset of psychosis before the age of 13 participated in 6- to 8-week open or double-blind trials of haloperidol (n = 15, mean dose 15." | 3.71 | Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. ( Alfaro, CL; Gochman, P; Lenane, M; Nicolson, R; Rapoport, JL; Sporn, A; Wudarsky, M, 2002) |
| " However, accumulating evidence suggests that these agents, particularly clozapine and olanzapine, have serious side effects of their own, including weight gain and elevated glucose and triglyceride levels." | 3.71 | The effects of novel antipsychotics on glucose and lipid levels. ( Ballon, JS; Boyd, JA; Marder, SR; Meng, LR; Wirshing, DA; Wirshing, WC, 2002) |
| " We report a 48 years old male drinker and addicted to cocaine, that after two months of Olanzapine use, developed a severe diabetes mellitus with fasting blood glucose values reaching 514 mg/dl." | 3.71 | [Diabetes mellitus induced by olanzapine. A case report]. ( Arancibia, P; Bravo, V; Rojas, P; Varela, S, 2001) |
| "The aim of this study was to evaluate the mechanisms underlying weight gain induced by the atypical antipsychotic, olanzapine." | 3.71 | Decrease of energy expenditure causes weight increase in olanzapine treatment - a case study. ( Franssila-Kallunki, A; Naukkarinen, H; Rissanen, A; Virkkunen, M; Wahlbeck, K, 2002) |
| "Three studies compared olanzapine and haloperidol given orally in maintenance therapy for schizophrenia and related psychoses." | 3.70 | Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. ( Beasley, CM; Dellva, MA; Tollefson, GD; Tran, PV; Wentley, AL, 1998) |
| "The aim of the present paper is to report a case of Neuroleptic Malignant Syndrome (NMS) occurring 2 days after olanzapine was added to the treatment regimen of an elderly patient with Schizoaffective Disorder." | 3.70 | Neuroleptic malignant syndrome associated with olanzapine. ( Bruxner, G; Johnson, V, 1998) |
| "Fourteen patients on treatment with olanzapine (all meeting DSM-IV criteria for schizophrenia or related psychoses) were studied." | 3.70 | Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. ( Brismar, KE; Hulting, AL; Melkersson, KI, 2000) |
| " Olanzapine is one of the atypical antipsychotics with efficacy for psychotic symptoms and a safer side-effect profile than typical antipsychotics." | 2.71 | The efficacy and safety of olanzapine for the treatment of geriatric psychosis. ( Hwang, JP; Lee, TW; Tsai, SJ; Yang, CH, 2003) |
| "Olanzapine-treated patients experienced a lower rate of treatment-emergent parkinsonism and akathisia but had significantly more weight gain, compared with the haloperidol-treated patients." | 2.71 | Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. ( Green, AI; Gur, RE; Hamer, RM; Kahn, R; Lieberman, JA; McEvoy, J; Perkins, D; Sharma, T; Tohen, M; Tollefson, G; Wei, H; Zipursky, R, 2003) |
| "Historical predictors were diagnosis of schizoaffective disorder, history or current use at baseline of alcohol or substance abuse, cigarette smoking, number of lifetime suicide attempts, and the number of hospitalizations in the previous 36 months to prevent suicide." | 2.71 | Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial. ( Alphs, L; Anand, R; Green, A; Hsu, C; Krishnan, KR; Meltzer, H; Potkin, SG; Young, FK, 2003) |
| " The treating clinician was free to vary or discontinue dosing and use additional medications." | 2.71 | A 1-year open-label trial of olanzapine in school-age children with schizophrenia. ( Adler, LE; Farley, GK; Novins, D; Ross, RG, 2003) |
| "Psychosis was assessed with the Neuropsychiatric Inventory/Nursing Home (NPI-NH) version and the Brief Psychiatric Rating Scale (BPRS)." | 2.70 | Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies. ( Clark, WS; Cummings, JL; Masterman, D; Street, J, 2002) |
| "Patients with schizoaffective disorder bipolar type, characterized as currently manic, mixed, depressed, or euthymic, were assessed weekly for 6 weeks during treatment with either olanzapine or haloperidol." | 2.70 | Olanzapine versus haloperidol in schizoaffective disorder, bipolar type. ( Breier, A; Feldman, PD; Keck, PE; Risser, RC; Tohen, M; Tran, PV; Zhang, F, 2001) |
| "Olanzapine is a recently introduced atypical neuroleptic agent for which little information is available on its use in children." | 2.69 | Open-label olanzapine treatment in five preadolescent children. ( King, BH; Krishnamoorthy, J, 1998) |
| "Haloperidol-treated first-episode patients experienced statistically significantly more extrapyramidal symptoms than haloperidol-treated multiple-episode patients." | 2.69 | Olanzapine versus haloperidol treatment in first-episode psychosis. ( Beasley, C; Grundy, S; Lieberman, JA; Sanger, TM; Tohen, M; Tollefson, GD, 1999) |
| "Olanzapine-treated patients achieved a statistically significant greater improvement than haloperidol treated patients on overall measures of efficacy, including clinical response." | 2.69 | Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy. ( Beasley, CM; Berg, PH; Lu, Y; Sanger, TM; Tollefson, GD; Tran, PV, 1999) |
| "Psychosis is a defining feature of schizophrenia consisting of formal thought disorder, delusions, and hallucinations." | 2.69 | The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome. ( Berg, PH; Breier, A, 1999) |
| "Olanzapine is a novel antipsychotic effective in reducing positive and negative symptoms of schizophrenia and with a safe side-effect profile." | 2.69 | Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. ( Brenner, R; Concepcion, NM; Florita, CD; Kaur, A; Madhusoodanan, S; Menon, G; Nunez, G; Reddy, H; Suresh, P, 2000) |
| "Olanzapine-treated patients had serum anticholinergic levels that were less than one fifth those of the clozapine-treated patients." | 2.69 | Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine. ( Brar, JS; Chengappa, KN; Kirshner, MA; Levine, J; Parepally, H; Pollock, BG; Zoretich, RA, 2000) |
| " The D2 receptor availability revealed an exponential dose-response relationship (r = - 0." | 2.69 | D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study. ( Dresel, S; Frodl, T; Hahn, K; Mager, T; Meisenzahl, EM; Möller, HJ; Preuss, UW; Rossmüller, B; Schmitt, GJ; Tatsch, K, 2000) |
| "However, diagnosis of schizoaffective disorder is included both in DSM-IV-TR and ICD-10." | 2.41 | [Schizoaffective disorder: clinical symptoms and present-day approach to treatment]. ( Danileviciūte, V, 2002) |
| " The manuscript describes the pharmacology, efficacy and tolerability studies, adverse effects and dosing considerations in the elderly." | 2.41 | Use of olanzapine for elderly patients with psychotic disorders: a review. ( Bogunovic, O; Brenner, R; Gupta, S; Madhusoodanan, S; Sinha, S, 2001) |
| "Risperidone appears to be an effective therapy, but several authors report cases of TD during treatment." | 2.41 | Tardive dyskinesias and antipsychotics: a review. ( Bayle, FJ; Chereau, I; Lancon, C; Llorca, PM, 2002) |
| " Dosing requirements for elderly patients tend to be much lower than those for younger adults." | 2.40 | Conventional vs. newer antipsychotics in elderly patients. ( Harris, MJ; Jeste, DV; Lacro, J; Lohr, JB; Rockwell, E, 1999) |
| "Olanzapine is a novel antipsychotic agent displaying a unique and pleotrophic pharmacology, which distinguishes it from other existing treatments." | 2.40 | Review of recent clinical studies with olanzapine. ( Kuntz, AJ; Tollefson, GD, 1999) |
| "The psychotic symptoms associated with Parkinson's disease can be as varied as the motor symptoms." | 2.40 | Management of psychotic aspects of Parkinson's disease. ( Juncos, JL, 1999) |
| " Published studies have drawn criticism in terms of inappropriate titration schedules, nonequivalent dosing between treatment groups, short treatment duration, and inadequate sample sizes." | 2.40 | Clozapine: a comparison with other novel antipsychotics. ( Fleischhacker, WW, 1999) |
| " Considerable progress has been made in improving the motor side effect profile with the advent of clozapine and risperidone." | 2.39 | Side effect profiles of new antipsychotic agents. ( Casey, DE, 1996) |
| " However, no correlation between prolactin levels and dosage could be found." | 1.32 | [Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics]. ( Fric, M; Laux, G, 2003) |
| "Patients reporting preexisting type 2 diabetes up to 8 months prior to observation were excluded." | 1.31 | Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. ( Gianfrancesco, FD; Grogg, AL; Mahmoud, RA; Nasrallah, HA; Wang, RH, 2002) |
| "Risperidone has a substantial cost advantage over olanzapine, and was preferred by psychiatrists for more indications." | 1.31 | Comparison of cost, dosage and clinical preference for risperidone and olanzapine. ( Kaplan, Z; Lichtenberg, P; Rabinowitz, J, 2000) |
| "Four patients affected by severe Parkinson's disease developed leucopenia (900-1200 WBC) during treatment of psychosis (3) or untreatable insomnia (1) with clozapine (37." | 1.31 | Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine. ( Bonanni, L; Gambi, F; Iacono, D; Onofrj, M; Thomas, A, 2000) |
| "Olanzapine is a relatively new antipsychotic agent which appears to be effective in the treatment of both the positive and negative symptoms of schizophrenia." | 1.30 | Olanzapine-induced mania. ( Brannon, GE; McBride, WA; Reeves, RR, 1998) |
| "Olanzapine is a new atypical antipsychotic agent that belongs to the same chemical class as clozapine." | 1.30 | In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study. ( Dresel, S; Hahn, K; Mager, T; Meisenzahl, E; Möller, HJ; Rossmüller, B; Tatsch, K, 1999) |
| "Twenty-one patients with Parkinson's disease and psychosis were included in an open-label 8-week trial of olanzapine." | 1.30 | Olanzapine for psychosis in patients with Parkinson's disease with and without dementia. ( Aarsland, D; Larsen, JP; Lim, NG; Tandberg, E, 1999) |
| "Weight gain has been reported with nearly every antipsychotic drug on the market (molindone is an exception)." | 1.30 | Weight gain associated with antipsychotic drugs. ( Ganguli, R, 1999) |
| "Risperidone was more commonly used in combination with benzodiazepines and anticholinergics than olanzapine and clozapine, while clozapine was less likely to be combined with antidepressants and mood stabilisers." | 1.30 | Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service. ( Altson, K; Bootle, A; Culhane, C; Doherty, P; Hope, J; Keks, NA; Krapivensky, N; Tanaghow, A, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 70 (36.46) | 18.2507 |
| 2000's | 121 (63.02) | 29.6817 |
| 2010's | 1 (0.52) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mao, M | 1 |
| Skogh, E | 1 |
| Scordo, MG | 1 |
| Dahl, ML | 1 |
| Linnet, K | 2 |
| Olesen, OV | 2 |
| Alfaro, CL | 1 |
| Wudarsky, M | 1 |
| Nicolson, R | 1 |
| Gochman, P | 1 |
| Sporn, A | 1 |
| Lenane, M | 1 |
| Rapoport, JL | 1 |
| Voruganti, L | 1 |
| Cortese, L | 1 |
| Owyeumi, L | 1 |
| Kotteda, V | 1 |
| Cernovsky, Z | 1 |
| Zirul, S | 1 |
| Awad, A | 1 |
| Friedman, JH | 1 |
| Fernandez, HH | 1 |
| Schmitt, GJ | 2 |
| Meisenzahl, EM | 2 |
| Dresel, S | 3 |
| Tatsch, K | 3 |
| Rossmüller, B | 3 |
| Frodl, T | 2 |
| Preuss, UW | 2 |
| Hahn, K | 3 |
| Möller, HJ | 3 |
| Sattar, SP | 3 |
| Gastfriend, DR | 1 |
| Livingston, M | 1 |
| Livingston, H | 1 |
| Carrasco, JL | 1 |
| Gutiérrez, M | 1 |
| Gómez, JC | 1 |
| Escobar, R | 1 |
| Alvarez, E | 1 |
| Cañas, F | 1 |
| Bobes, J | 1 |
| Gascón, J | 1 |
| Gibert, J | 1 |
| Wirshing, DA | 2 |
| Boyd, JA | 1 |
| Meng, LR | 1 |
| Ballon, JS | 1 |
| Marder, SR | 2 |
| Wirshing, WC | 2 |
| Gianfrancesco, FD | 1 |
| Grogg, AL | 1 |
| Mahmoud, RA | 1 |
| Wang, RH | 1 |
| Nasrallah, HA | 1 |
| Lindenmayer, JP | 7 |
| Czobor, P | 5 |
| Volavka, J | 6 |
| Lieberman, JA | 10 |
| Citrome, L | 6 |
| Sheitman, B | 5 |
| Chakos, M | 5 |
| McEvoy, JP | 3 |
| Daniel, DG | 1 |
| Meltzer, HY | 3 |
| Alphs, L | 2 |
| Green, AI | 2 |
| Altamura, AC | 1 |
| Anand, R | 2 |
| Bertoldi, A | 1 |
| Bourgeois, M | 1 |
| Chouinard, G | 1 |
| Islam, MZ | 1 |
| Kane, J | 1 |
| Krishnan, R | 1 |
| Potkin, S | 1 |
| Caro, JJ | 1 |
| Ward, A | 1 |
| Levinton, C | 1 |
| Robinson, K | 1 |
| Matthews, JD | 1 |
| Bottonari, KA | 1 |
| Polania, LM | 1 |
| Mischoulon, D | 1 |
| Dording, CM | 1 |
| Irvin, R | 1 |
| Fava, M | 1 |
| Danileviciūte, V | 1 |
| Duggan, L | 2 |
| Fenton, M | 2 |
| Dardennes, RM | 2 |
| El-Dosoky, A | 2 |
| Indran, S | 2 |
| Cooper, TB | 4 |
| Meibach, RC | 1 |
| Hwang, JP | 1 |
| Yang, CH | 1 |
| Lee, TW | 1 |
| Tsai, SJ | 1 |
| Miller, TJ | 2 |
| Zipursky, RB | 2 |
| Perkins, D | 3 |
| Addington, J | 2 |
| Woods, SW | 4 |
| Hawkins, KA | 2 |
| Hoffman, R | 2 |
| Preda, A | 1 |
| Epstein, I | 1 |
| Addington, D | 1 |
| Lindborg, S | 2 |
| Marquez, E | 1 |
| Tohen, M | 6 |
| Breier, A | 9 |
| McGlashan, TH | 2 |
| Taylor, DM | 1 |
| Wright, T | 1 |
| Libretto, SE | 1 |
| Jerrell, JM | 1 |
| Bloch, Y | 1 |
| Vardi, O | 1 |
| Mendlovic, S | 1 |
| Levkovitz, Y | 1 |
| Gothelf, D | 1 |
| Ratzoni, G | 1 |
| Gurovich, I | 1 |
| Vempaty, A | 1 |
| Lippmann, S | 1 |
| Kopf, A | 1 |
| Köster, J | 1 |
| Schulz, A | 1 |
| Krömker, H | 1 |
| Becker, T | 1 |
| Tollefson, G | 1 |
| Gur, RE | 1 |
| Kahn, R | 1 |
| McEvoy, J | 3 |
| Sharma, T | 1 |
| Zipursky, R | 1 |
| Wei, H | 1 |
| Hamer, RM | 2 |
| Potkin, SG | 1 |
| Hsu, C | 1 |
| Krishnan, KR | 1 |
| Young, FK | 1 |
| Meltzer, H | 1 |
| Green, A | 1 |
| Lambert, M | 1 |
| Holzbach, R | 1 |
| Moritz, S | 1 |
| Postel, N | 1 |
| Krausz, M | 1 |
| Naber, D | 1 |
| Bokszanska, A | 1 |
| Martin, G | 1 |
| Vanstraelen, M | 1 |
| Holt, G | 2 |
| Bouras, N | 2 |
| Taylor, D | 1 |
| Grant, K | 1 |
| Bhatia, S | 1 |
| Petty, F | 1 |
| Schatz, RA | 1 |
| Raja, M | 1 |
| Azzoni, A | 1 |
| Bhatia, SC | 1 |
| Reeves, RR | 2 |
| Torres, RA | 1 |
| Harvey, PD | 1 |
| Napolitano, JA | 1 |
| Mao, L | 1 |
| Gharabawi, G | 1 |
| Fric, M | 1 |
| Laux, G | 1 |
| Sikich, L | 1 |
| Bashford, RA | 1 |
| Sheitman, BB | 1 |
| Karagianis, JL | 3 |
| LeDrew, KK | 1 |
| Walker, DJ | 1 |
| Feldman, PD | 5 |
| Kaiser, CJ | 1 |
| Kennedy, JS | 1 |
| Sutton, VK | 1 |
| Tran, PV | 7 |
| Tollefson, GD | 10 |
| Zhang, F | 2 |
| Archie, S | 1 |
| Wilson, JH | 1 |
| Osborne, S | 1 |
| Hobbs, H | 1 |
| McNiven, J | 1 |
| Ross, RG | 1 |
| Novins, D | 1 |
| Farley, GK | 1 |
| Adler, LE | 1 |
| Hoeh, N | 1 |
| Gyulai, L | 1 |
| Weintraub, D | 1 |
| Streim, J | 1 |
| Baksh, A | 1 |
| Waage, IM | 1 |
| Gedde-Dahl, A | 1 |
| Fibiger, HC | 1 |
| Wolters, EC | 1 |
| Jansen, EN | 1 |
| Tuynman-Qua, HG | 1 |
| Bergmans, PL | 1 |
| Casey, DE | 2 |
| Lehman, AF | 1 |
| Fulton, B | 1 |
| Goa, KL | 1 |
| Beasley, CM | 5 |
| Street, JS | 4 |
| Krueger, JA | 1 |
| Tamura, RN | 3 |
| Graffeo, KA | 1 |
| Thieme, ME | 1 |
| Reus, VI | 1 |
| Glazer, WM | 1 |
| Meyer, JM | 1 |
| Simpson, GM | 1 |
| Potvin, JH | 2 |
| Hamilton, SH | 1 |
| Kuntz, AJ | 2 |
| Andersen, SW | 1 |
| Beasley, C | 2 |
| Weizer, M | 1 |
| Levy, A | 1 |
| Davidson, M | 1 |
| Schooler, NR | 2 |
| Zarate, CA | 1 |
| Hillard, JR | 1 |
| al Jeshi, A | 1 |
| Gheuens, J | 1 |
| Grebb, JA | 1 |
| Gupta, S | 2 |
| Droney, T | 1 |
| Al-Samarrai, S | 1 |
| Keller, P | 1 |
| Frank, B | 1 |
| Kasper, S | 1 |
| Küfferle, B | 1 |
| Landry, P | 1 |
| Cournoyer, J | 1 |
| Krishnamoorthy, J | 1 |
| King, BH | 1 |
| Phan, TG | 1 |
| Yu, RY | 1 |
| Hersch, MI | 1 |
| Rudnick, A | 1 |
| Spellberg, BJ | 1 |
| Erhart, SM | 1 |
| Bruneau, MA | 1 |
| Stip, E | 1 |
| Rosen, EH | 1 |
| McBride, WA | 1 |
| Brannon, GE | 1 |
| Dellva, MA | 1 |
| Wentley, AL | 1 |
| Gazzola, LR | 1 |
| Opler, LA | 1 |
| Sanger, TM | 3 |
| Grundy, S | 1 |
| Jeste, DV | 3 |
| Rockwell, E | 1 |
| Harris, MJ | 1 |
| Lohr, JB | 1 |
| Lacro, J | 1 |
| Fertig, MK | 1 |
| Brooks, VG | 1 |
| Shelton, PS | 1 |
| English, CW | 1 |
| Sanders, RD | 1 |
| Mossman, D | 1 |
| Soutullo, CA | 1 |
| Keck, PE | 3 |
| McElroy, SL | 1 |
| Johnson, V | 1 |
| Bruxner, G | 1 |
| Kane, JM | 1 |
| Reich, J | 1 |
| Lu, Y | 1 |
| Berg, PH | 2 |
| Tandon, R | 1 |
| Milner, K | 1 |
| Jibson, MD | 1 |
| Juncos, JL | 1 |
| Buckley, PF | 1 |
| Fanous, A | 1 |
| Fleischhacker, WW | 1 |
| Swartz, C | 1 |
| Walder, M | 1 |
| Mager, T | 2 |
| Meisenzahl, E | 1 |
| Aarsland, D | 1 |
| Larsen, JP | 1 |
| Lim, NG | 1 |
| Tandberg, E | 1 |
| Weiss, EL | 1 |
| Longhurst, JG | 1 |
| Bowers, MB | 1 |
| Mazure, CM | 1 |
| Stahl, SM | 1 |
| Vercueil, L | 1 |
| Foucher, J | 1 |
| Madhusoodanan, S | 3 |
| Suresh, P | 2 |
| Brenner, R | 3 |
| Pillai, R | 1 |
| Meissner, W | 1 |
| Schmidt, T | 1 |
| Kupsch, A | 1 |
| Trottenberg, T | 1 |
| Lempert, T | 1 |
| Benazzi, F | 2 |
| Kostakoğlu, AE | 1 |
| Rezaki, M | 1 |
| Göğüş, A | 1 |
| Ganguli, R | 1 |
| Gheorghiu, S | 1 |
| Knobler, HY | 1 |
| Drumer, D | 1 |
| Wolfgang, SA | 1 |
| Simon, AE | 2 |
| Aubry, JM | 2 |
| Malky, L | 1 |
| Bertschy, G | 2 |
| Osser, DN | 1 |
| Najarian, DM | 1 |
| Dufresne, RL | 1 |
| Olie, JP | 1 |
| Ghaoui, S | 1 |
| Bayle, FJ | 2 |
| Keks, NA | 1 |
| Altson, K | 1 |
| Hope, J | 1 |
| Krapivensky, N | 1 |
| Culhane, C | 1 |
| Tanaghow, A | 1 |
| Doherty, P | 1 |
| Bootle, A | 1 |
| Solomons, K | 1 |
| Geiger, O | 1 |
| Compton, MT | 2 |
| Saldivia, A | 1 |
| Berry, SA | 1 |
| Concepcion, NM | 1 |
| Florita, CD | 1 |
| Menon, G | 1 |
| Kaur, A | 1 |
| Nunez, G | 1 |
| Reddy, H | 1 |
| Conley, RR | 2 |
| Chengappa, KN | 1 |
| Pollock, BG | 2 |
| Parepally, H | 1 |
| Levine, J | 1 |
| Kirshner, MA | 1 |
| Brar, JS | 1 |
| Zoretich, RA | 1 |
| Williams, H | 1 |
| Clarke, R | 1 |
| Martin, J | 1 |
| Karagianis, J | 1 |
| Pillmann, F | 1 |
| Schlote, K | 1 |
| Broich, K | 1 |
| Marneros, A | 1 |
| Singh, HK | 1 |
| Markowitz, GD | 1 |
| Myers, G | 1 |
| Haberfellner, EM | 1 |
| Rigalleau, V | 1 |
| Gatta, B | 1 |
| Bonnaud, S | 1 |
| Masson, M | 1 |
| Bourgeois, ML | 1 |
| Vergnot, V | 1 |
| Gin, H | 1 |
| Clark, WS | 4 |
| Gannon, KS | 1 |
| Cummings, JL | 2 |
| Bymaster, FP | 1 |
| Mitan, SJ | 2 |
| Kadam, DL | 2 |
| Rhoads, E | 1 |
| Melkersson, KI | 1 |
| Hulting, AL | 1 |
| Brismar, KE | 1 |
| Kinon, BJ | 2 |
| Basson, BR | 2 |
| Gilmore, JA | 2 |
| Malcolm, S | 1 |
| Stauffer, VL | 1 |
| Teter, CJ | 1 |
| Early, JJ | 1 |
| Frachtling, RJ | 1 |
| Rabinowitz, J | 1 |
| Lichtenberg, P | 1 |
| Kaplan, Z | 1 |
| Weintraub, E | 1 |
| Robinson, C | 1 |
| Feifel, D | 1 |
| Ghaemi, SN | 1 |
| Stolar, M | 1 |
| Sernyak, MJ | 1 |
| Charney, DS | 1 |
| Schmitt, A | 1 |
| Braus, DF | 1 |
| Littrell, KH | 1 |
| Johnson, CG | 1 |
| Hilligoss, NM | 1 |
| Peabody, CD | 1 |
| Littrell, SH | 1 |
| Onofrj, M | 1 |
| Thomas, A | 1 |
| Bonanni, L | 1 |
| Iacono, D | 1 |
| Gambi, F | 1 |
| Kapur, S | 1 |
| Seeman, P | 1 |
| Dawe, IC | 1 |
| Thakur, A | 1 |
| Bégin, S | 1 |
| Raskin, J | 1 |
| Roychowdhury, SM | 1 |
| Czekalla, J | 1 |
| Kollack-Walker, S | 1 |
| Floris, M | 1 |
| Lejeune, J | 1 |
| Deberdt, W | 1 |
| Risch, SC | 1 |
| McGurk, S | 1 |
| Horner, MD | 1 |
| Nahas, Z | 1 |
| Owens, SD | 1 |
| Molloy, M | 1 |
| Gilliard, C | 1 |
| Christie, S | 1 |
| Markowitz, JS | 1 |
| DeVane, CL | 1 |
| Mintzer, J | 1 |
| George, MS | 1 |
| Mahmoud, R | 1 |
| Goodnick, PJ | 1 |
| Barrios, CA | 1 |
| Zorn, SH | 1 |
| Miller, AH | 1 |
| Narendran, R | 1 |
| Young, CM | 1 |
| Valenti, AM | 1 |
| Pristach, CA | 1 |
| Pato, MT | 1 |
| Grace, JJ | 1 |
| Khan, A | 1 |
| Khan, SR | 1 |
| Leventhal, RM | 1 |
| Brown, WA | 1 |
| Haapasalo-Pesu, KM | 1 |
| Saarijärvi, S | 1 |
| Dervaux, A | 1 |
| Mascarenhas, N | 1 |
| Lambolez, T | 1 |
| Malek-Ahmadi, P | 1 |
| Simpson, MM | 1 |
| Goetz, RR | 1 |
| Devlin, MJ | 1 |
| Goetz, SA | 1 |
| Walsh, BT | 1 |
| Friedlander, R | 1 |
| Lazar, S | 1 |
| Klancnik, J | 1 |
| Songer, DA | 1 |
| Barclay, JC | 1 |
| Schneider, LS | 1 |
| Tariot, PN | 1 |
| Lyketsos, CG | 1 |
| Dagerman, KS | 1 |
| Davis, KL | 1 |
| Davis, S | 1 |
| Hsiao, JK | 1 |
| Katz, IR | 1 |
| Olin, JT | 1 |
| Rabins, PV | 1 |
| Rosenheck, RA | 1 |
| Small, GW | 1 |
| Lebowitz, B | 1 |
| Chroni, E | 1 |
| Lekka, NP | 1 |
| Tsibri, E | 1 |
| Economou, A | 1 |
| Paschalis, C | 1 |
| Juliar, BE | 1 |
| Baptista, T | 1 |
| Beaulieu, S | 1 |
| Rojas, P | 1 |
| Arancibia, P | 1 |
| Bravo, V | 1 |
| Varela, S | 1 |
| Van Meter, SA | 1 |
| Seaburg, H | 1 |
| McLendon, B | 1 |
| Doraiswamy, PM | 1 |
| Nelson, EB | 1 |
| Rielage, E | 1 |
| Welge, JA | 1 |
| Ellingrod, VL | 1 |
| Schultz, SK | 1 |
| Ekstam-Smith, K | 1 |
| Kutscher, E | 1 |
| Turvey, C | 1 |
| Arndt, S | 1 |
| Parker, G | 1 |
| Malhi, G | 1 |
| Street, J | 1 |
| Masterman, D | 1 |
| Risser, RC | 1 |
| de Haan, L | 1 |
| Beuk, N | 1 |
| Hoogenboom, B | 1 |
| Dingemans, P | 1 |
| Linszen, D | 1 |
| Fawcett, RG | 1 |
| Mathias, S | 1 |
| Schaaf, LW | 1 |
| Sonntag, A | 1 |
| Ramankutty, G | 1 |
| Sinha, S | 1 |
| Bogunovic, O | 1 |
| Riccitelli, G | 1 |
| Baker, N | 1 |
| Bilder, RM | 1 |
| Goldman, RS | 1 |
| Hoptman, M | 1 |
| Kunz, M | 1 |
| Horowitz, TL | 1 |
| Llorca, PM | 1 |
| Chereau, I | 1 |
| Lancon, C | 1 |
| Del Paggio, D | 1 |
| Finley, PR | 1 |
| Cavano, JM | 1 |
| Patel, NC | 1 |
| Dorson, PG | 1 |
| Edwards, N | 1 |
| Mendelson, S | 1 |
| Crismon, ML | 1 |
| Virkkunen, M | 1 |
| Wahlbeck, K | 1 |
| Rissanen, A | 1 |
| Naukkarinen, H | 1 |
| Franssila-Kallunki, A | 1 |
| Mendhekar, DN | 1 |
| War, L | 1 |
| Sharma, JB | 1 |
| Jiloha, RC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Transcranial Magnetic Stimulation for Individuals With Tourette's Syndrome[NCT00529308] | Phase 2 | 20 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Aripiprazole for Clozapine Associated Medical Morbidity[NCT00345033] | Phase 4 | 38 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia[NCT00351000] | Phase 4 | 24 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department[NCT04260607] | Phase 3 | 2 participants (Actual) | Interventional | 2020-01-14 | Terminated (stopped due to As a busy MTF we were unable to retain a health care provider with the appropriate expertise to buy-in to this study once the initiating PI left military service.) | ||
| Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness[NCT00661869] | 295 participants (Actual) | Interventional | 2006-09-30 | Completed | |||
| A Double-Blind, Placebo-Controlled Trial of Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment: Bergman's Minimal Model Analysis[NCT00337350] | Phase 4 | 20 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| A Clinical Trial Of Weight Reduction in Schizophrenia[NCT00158366] | 261 participants (Actual) | Interventional | 2004-05-31 | Completed | |||
| A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia[NCT00351936] | Phase 4 | 16 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Switching Antipsychotics: Abrupt Discontinuation Versus Overlap[NCT02640300] | Phase 4 | 33 participants (Actual) | Interventional | 1999-05-31 | Completed | ||
| [NCT01615185] | Phase 4 | 96 participants (Actual) | Interventional | 2008-01-31 | Terminated | ||
| Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial)[NCT00015548] | 450 participants | Interventional | 2001-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 2 |
| Sham | 8 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 1 |
| Sham | 0 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56.5 |
| Sham | 63.8 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56 |
| Sham | 59.8 |
Y-GTSS is a clinician-rated scale used to assess tic severity. Motor and phonic tics are rated separately from 0 to 5 on several scales including number, frequency, intensity, complexity, and interference. Thus Motor and Phonic Tic scores can range from 0 to 25; the combined Total Tic Score ranges from 0 to 50. There is also an Impairment score that rates the overall burden due to tics. The Impairment scale yields a single score from 0 to 50 with higher scores indicating higher levels of overall impairment associated with tics. (NCT00529308)
Timeframe: 3 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active | 29.5 |
| Sham | 31.5 |
A comparison between aripiprazole group and placebo group of change in Body Mass Index (BMI) measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | kg/m^2 (Mean) |
|---|---|
| Aripiprazole | -0.52 |
| Placebo | 0.03 |
A comparison between the aripiprazole group and placebo group in change in glucose metabolism measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | min^-1 (Mean) |
|---|---|
| Aripiprazole | 0.003 |
| Placebo | -0.005 |
A comparison between aripiprazole group and placebo group of change in insulin resistance measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Aripiprazole | 0.6 |
| Placebo | 0.65 |
A comparison of aripiprazole group and placebo group in change in total cholesterol measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -15.3 |
| Placebo | 5.6 |
(NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -5.9 |
| Placebo | -7.3 |
A comparison between aripiprazole group and placebo group in change in weight measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | kg (Mean) |
|---|---|
| Aripiprazole | -1.5 |
| Placebo | 0.3 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting glucose levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | mg/dL (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 5 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -4.5 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting insulin levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | microIU/L (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 1 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -0.9 |
Acute insulin response to glucose (AIRG) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in SG between Baseline and week 8. AIRG was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. AIRG measures the acute(0-10 min) beta cell response to a glucose load calculated by the areas under the curve higher than basal insulin values. The AIRG was assessed as the incremental area under the curve (calculated by the trapezoid rule) from 0 to 10 min of the FSIVGTT. (NCT00337350)
Timeframe: baseline, week 8
| Intervention | Units/mL per 10 minutes (Mean) |
|---|---|
| Rosiglitazone | -151 |
| Placebo | 19 |
Insulin Sensitivity (IS) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in IS between Baseline and week 8. SI was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. SI represents the increase in net fractional glucose clearance rate per unit change in serum insulin concentration after the intravenous glucose load (microUnits/mL). (NCT00337350)
Timeframe: baseline, week 8
| Intervention | microUnits/mL (Mean) |
|---|---|
| Rosiglitazone | 3.2 |
| Placebo | 0.4 |
Glucose utilization (SG) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in SG between Baseline and week 8. SG was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. SG represents the net fractional glucose clearance rate because of the increase in glucose independent of any increase in circulating insulin concentrations above baseline. (NCT00337350)
Timeframe: baseline, week 8
| Intervention | min^-1 (Mean) |
|---|---|
| Rosiglitazone | .002 |
| Placebo | -0.01 |
Evaluating change in Body Mass Index (BMI) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | kg/m^2 (Mean) |
|---|---|
| Aripiprazole | -0.4 |
| Placebo | 0.3 |
Evaluating change in fasting total cholesterol between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -3 |
| Placebo | 9 |
Evaluating change in high-density lipoprotein cholesterol (HDL-C) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | 0.4 |
| Placebo | 0.6 |
Evaluating change in low-density lipoprotein (LDL) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -0.2 |
| Placebo | 3.1 |
Evaluating change in triglyceride levels between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -51.7 |
| Placebo | 47.6 |
Evaluating change in waist-hip ratio (WHR) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | cm (Mean) |
|---|---|
| Aripiprazole | 0.0 |
| Placebo | 0.0 |
Evaluating change in weight (lbs) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | lbs (Mean) |
|---|---|
| Aripiprazole | -2.9 |
| Placebo | 2.1 |
40 reviews available for pirenzepine and Psychotic Disorders
| Article | Year |
|---|---|
Atypical antipsychotics in Parkinson-sensitive populations.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Dementia, Vascular; Dibenzothia | 2002 |
Using antipsychotics in elderly patients.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Delusions; Hallucinations; Humans; Olanzapine; Pirenzep | 2002 |
Recent developments in pharmacotherapy for the acutely psychotic patient.
Topics: Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Injections, Intr | 2002 |
[Schizoaffective disorder: clinical symptoms and present-day approach to treatment].
Topics: Adolescent; Amisulpride; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Antimanic | 2002 |
Olanzapine for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psychotic Disorders; Randomi | 2003 |
[Life threatening neuroleptic malignant syndrome due to olanzapine].
Topics: Antipsychotic Agents; Benzodiazepines; Critical Care; Electroconvulsive Therapy; Female; Haloperidol | 2003 |
Olanzapine for psychotic and behavioral disturbances in Alzheimer disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Humans; Mental Disorders; Olanzapine; Pire | 2003 |
Pharmacologic management of psychosis in the elderly: a critical review.
Topics: Aged; Alzheimer Disease; Benzodiazepines; Bipolar Disorder; Clozapine; Depressive Disorder; Drug Adm | 2003 |
Olanzapine: a new typical antipsychotic drug.
Topics: Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Humans; Olanzapine; Pirenzepine; Ps | 1996 |
Side effect profiles of new antipsychotic agents.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; | 1996 |
Evaluating outcomes of treatments for persons with psychotic disorders.
Topics: Antipsychotic Agents; Benzodiazepines; Drug Costs; Health Care Reform; Humans; Olanzapine; Pirenzepi | 1996 |
Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psychotic Disorders | 1997 |
Olanzapine and the new generation of antipsychotic agents: patterns of use.
Topics: Antipsychotic Agents; Benzodiazepines; Child; Comorbidity; Dementia; Depressive Disorder; Developmen | 1997 |
[New antipsychotic drugs].
Topics: Antipsychotic Agents; Benzodiazepines; Benzothiazoles; Clinical Trials as Topic; Dibenzothiazepines; | 1997 |
New antipsychotic medications: strategies for evaluation and selected findings.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clinical Trials as Topic; Clozapine; Drug Ad | 1997 |
Antipsychotic agents and bipolar disorder.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Cl | 1998 |
Emergency treatment of acute psychosis.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Decision Trees; Drug Administration | 1998 |
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Tri | 1998 |
Conventional vs. newer antipsychotics in elderly patients.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Dementia; Dibenzothiazepines; Dose-Re | 1999 |
Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Disease Progressio | 1999 |
Tardive dyskinesia in affective disorders.
Topics: Adult; Affective Disorders, Psychotic; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipol | 1999 |
Review of recent clinical studies with olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Depressive Disorder; Drug Resistance; Humans; Olan | 1999 |
Antipsychotics from theory to practice: integrating clinical and basic data.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Trials as Topic; Cl | 1999 |
Management of psychotic aspects of Parkinson's disease.
Topics: Algorithms; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; C | 1999 |
The role of typical and atypical antipsychotic medications in the management of agitation and aggression.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Loxapine; Mental Disorders; Ol | 1999 |
Clozapine: a comparison with other novel antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; Double-Blind | 1999 |
[New antipsychotic agents].
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Imidazole | 1999 |
Olanzapine for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psychotic Disorders; Schizop | 2000 |
Adverse events related to olanzapine.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Mass In | 2000 |
Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dose-Response Relationship, Drug; Fe | 2000 |
Rationale and guidelines for the inpatient treatment of acute psychosis.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Administration Schedule; Drug | 2000 |
New treatments for bipolar disorder: the role of atypical neuroleptic agents.
Topics: Acute Disease; Algorithms; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazep | 2000 |
Consistency of atypical antipsychotic superiority to placebo in recent clinical trials.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dibenzothiazepines; Humans; Olanzap | 2001 |
Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.
Topics: Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Dopamine D2 Receptor Antagonists; Haloperid | 2001 |
Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics.
Topics: Acute Disease; Antipsychotic Agents; Arrhythmias, Cardiac; Benzodiazepines; Death, Sudden; Female; H | 2001 |
Use of olanzapine in non-psychotic psychiatric disorders.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorder; Humans; Ol | 2001 |
The pharmacology of weight gain with antipsychotics.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Eating; Humans; Olanz | 2001 |
Priapism associated with conventional and atypical antipsychotic medications: a review.
Topics: Antipsychotic Agents; Benzodiazepines; Circadian Rhythm; Clozapine; Erectile Dysfunction; Female; Fo | 2001 |
Use of olanzapine for elderly patients with psychotic disorders: a review.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psychotic Disorders; R | 2001 |
Tardive dyskinesias and antipsychotics: a review.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; Humans; Ola | 2002 |
55 trials available for pirenzepine and Psychotic Disorders
| Article | Year |
|---|---|
Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Huma | 2002 |
Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine.
Topics: Adult; Aged; Antipsychotic Agents; Benzamides; Benzodiazepines; Contrast Media; Corpus Striatum; Dop | 2002 |
Treatment of severely psychotic inpatients with schizophrenia: olanzapine versus other antipsychotic drugs.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; | 2002 |
Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cross-Over Studies; Double-Bli | 2002 |
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Humans; Male; Middle Ag | 2003 |
An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Depressive Disord | 2002 |
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; Clozapine; Double-Bl | 2003 |
The efficacy and safety of olanzapine for the treatment of geriatric psychosis.
Topics: Acute Disease; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; | 2003 |
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Comorbidity; Depressive | 2003 |
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Child; Diagnostic and Statistical Manual o | 2003 |
Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Diagnostic and Stat | 2002 |
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Metho | 2003 |
Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Humans; Male; Middle Aged; Ol | 2003 |
Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Fe | 2003 |
Risperidone and olanzapine in adults with intellectual disability: a clinical naturalistic study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Comorbidity; Di | 2003 |
Potential use of olanzapine in treatment of substance dependence disorders.
Topics: Alcoholism; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Cocaine-Related Disorders; Huma | 2003 |
Comparison of three antipsychotics in the emergency psychiatric setting.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Emergency Services, | 2003 |
Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Double-Blind Method; Female; Human | 2003 |
A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Dose-Response Relationship, Drug; Double-B | 2004 |
Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Follow-Up Studies; Hospitalization; Humans; Ma | 2003 |
A 1-year open-label trial of olanzapine in school-age children with schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Drug Resistance; Female; Humans; Male; Ola | 2003 |
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depre | 1997 |
Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Drug Administration | 1997 |
Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Dyskinesia, Drug-Induced; Female; | 1997 |
Comments on "Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders" by Tran and Associates.
Topics: Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Humans; Olanzapine; Pirenzepine; Psychot | 1998 |
Open-label olanzapine treatment in five preadolescent children.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Benzod | 1998 |
Olanzapine versus haloperidol treatment in first-episode psychosis.
Topics: Age of Onset; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatric Ratin | 1999 |
An open trial of olanzapine in patients with treatment-refractory psychoses.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Monitoring; Female; Humans; Male; Middle Aged; Ol | 1999 |
Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperido | 1999 |
Schizophrenia and schizoaffective disorder treated with high doses of olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Double-Blind Method; | 1999 |
The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Double-Blind Method; | 1999 |
Olanzapine in whole, not half, tablets for psychosis from Alzheimer's dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Humans; Olanzapine; P | 1999 |
Olanzapine increases weight and serum triglyceride levels.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Female; Hospitalizat | 1999 |
Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Drug Interactions; Dyskinesia, Drug- | 2000 |
Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine.
Topics: Adult; Antipsychotic Agents; Atropine; Autonomic Nervous System Diseases; Benzodiazepines; Cholinerg | 2000 |
Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Behavioral Symptoms; Benzodiazepin | 2000 |
Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Drug Administrat | 2000 |
D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Benzodiazepines; Brain; Brain Chemi | 2000 |
Switching clozapine responders to olanzapine.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Adm | 2000 |
The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Delus | 2001 |
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Blood Pressure; Body Mass Index; Body W | 2001 |
Effect of amantadine on weight gain during olanzapine treatment.
Topics: Adult; Amantadine; Antipsychotic Agents; Benzodiazepines; Dopamine Agents; Female; Humans; Male; Ola | 2001 |
A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates.
Topics: Adult; Basal Ganglia; Benzodiazepines; Brain; Brain Mapping; Cognition Disorders; Cross-Over Studies | 2001 |
A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Method; Drug Admi | 2001 |
Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study.
Topics: Adult; Affective Disorders, Psychotic; Aged; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; | 2001 |
Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Double-Bl | 2001 |
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.
Topics: Aged; Algorithms; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Citalopram; Cost-Benefit | 2001 |
Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavioral Symptoms; Benzodiazepines; Dose-Response Rela | 2001 |
An open trial of olanzapine in the treatment of patients with psychotic depression.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Female; Humans; Male; Olan | 2001 |
Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cognition; Dementia; Female; Humans; | 2002 |
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Double-Blind M | 2002 |
Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Behavior; Benzodiazepines; Cognition; Delusions; Dose | 2002 |
Olanzapine versus haloperidol in schizoaffective disorder, bipolar type.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind M | 2001 |
Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Comorbidity; Female; Humans; Longitudin | 2002 |
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Double-Blind Method; Female; Hal | 2002 |
97 other studies available for pirenzepine and Psychotic Disorders
| Article | Year |
|---|---|
Interindividual variation in olanzapine concentration influenced by UGT1A4 L48V polymorphism in serum and upstream FMO polymorphisms in cerebrospinal fluid.
Topics: Antipsychotic Agents; Benzodiazepines; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Female; Hum | 2012 |
Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication.
Topics: Adult; Aged; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Carbamazepine; Chromatography, | 2002 |
Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Child; Clozapine; Double-Blind Method; Fem | 2002 |
Olanzapine-induced hyperventilation: case report.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Humans; Hyperventilation; Male; Olanzapine; Pirenzepin | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Comorbidity; Confidence Inte | 2002 |
The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Diabetes Mellitus; Female; Follow-Up St | 2002 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Trials as Topic; Clozapine; | 2003 |
Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Cost-Benefit Analysis; Costs and Cost | 2003 |
Hyperglycemia from olanzapine treatment in adolescents.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Diabetes Mellitus, Type 2; Female; | 2003 |
QTc prolongation: chlorpromazine and high-dosage olanzapine.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Female; Health Status | 2003 |
Olanzapine for cocaine cravings and relapse prevention.
Topics: Antipsychotic Agents; Behavior, Addictive; Benzodiazepines; Cocaine-Related Disorders; Comorbidity; | 2003 |
Orally disintegrating olanzapine for the treatment of psychotic and behavioral disturbances associated with dementia.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Benzodiazepi | 2003 |
[Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzothiaze | 2003 |
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Depression; Double | 2003 |
Pilot study: access to fitness facility and exercise levels in olanzapine-treated patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Exercise; Female; Fitness Centers; Health | 2003 |
High-dose olanzapine and prolactin levels.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug | 2003 |
Pulmonary embolism possibly associated with olanzapine treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Humans; Male; Olanzapine; Pirenzepine; Psychotic Disor | 2003 |
Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Middle Aged; Olanzapine; Parkinso | 1996 |
Antipsychotic drug choices now include olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psychotic Disorders | 1996 |
Olanzapine: a novel atypical neuroleptic agent.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Humans; Olanzapine; Pirenzepine; Ps | 1997 |
From chlorpromazine to olanzapine: a brief history of antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; History, 20th Century; Humans; Ola | 1997 |
Paranoia and agitation associated with olanzapine treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanzapine; Paranoid Disorders; | 1998 |
Comments on article by Tran and colleagues, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders".
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psychotic Disorders; Risperi | 1998 |
Comments on article by Tran and associates, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders".
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psychotic Disorders; Risperi | 1998 |
Olanzapine-induced weight gain.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Middle Aged; Olanzapine; P | 1998 |
Acute dystonia with olanzapine.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Dystonia; Female; Humans; Male; Middle Aged; O | 1998 |
Hypothermia induced by risperidone and olanzapine in a patient with Prader-Willi syndrome.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Humans; Hypothermia | 1998 |
Quality of life and atypical antipsychotics.
Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psych | 1998 |
Novel antipsychotics and new onset diabetes.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2; Humans; Male; Mi | 1998 |
Metronome or alternating Pisa syndrome: a form of tardive dystonia under clozapine treatment.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; Female; Humans; Middle A | 1998 |
Olanzapine and negative symptoms.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Male; Middle Aged; Olanzapine; Pire | 1998 |
Olanzapine-induced mania.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Male; Olanzapine; Pirenzepin | 1998 |
Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Hal | 1998 |
Return of menstruation after switching from risperidone to olanzapine.
Topics: Adult; Amenorrhea; Antipsychotic Agents; Benzodiazepines; Female; Humans; Menstruation; Olanzapine; | 1998 |
Hyperglycemia associated with olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; | 1998 |
Olanzapine in the treatment of tardive dyskinesia: a report of two cases.
Topics: Adult; Alcoholism; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Humans; Male; Mi | 1999 |
Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cytochrome P-450 CYP2D6 Inhibitors; Drug I | 1999 |
Neuroleptic malignant syndrome associated with olanzapine.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Diagnosis, Differential; Humans; Male; Neuroleptic Mali | 1998 |
New antipsychotic drugs produce better outcomes.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Disease Management; Drug Costs; Humans; Mental Hea | 1997 |
Use of high-dose olanzapine in refractory psychosis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Humans; Male; Olanzapine | 1999 |
Hypofrontal symptoms from olanzapine: a case report.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Humans; Male; Olanzapine; Pirenzepine; Psychotic Disor | 1999 |
In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Benzodiazepines; Case-Control Studi | 1999 |
Olanzapine for psychosis in patients with Parkinson's disease with and without dementia.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Dementia; Dose-Response Relationship, Drug; Female; Hum | 1999 |
Olanzapine for treatment-refractory psychosis in patients responsive to, but intolerant of, clozapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Female; H | 1999 |
Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Therapy, Combination; Hum | 1999 |
Risperidone-induced tardive dystonia and psychosis.
Topics: Antipsychotic Agents; Benzodiazepines; Dystonia; Facial Muscles; Humans; Male; Middle Aged; Neck Mus | 1999 |
Experience with the atypical antipsychotics--risperidone and olanzapine in the elderly.
Topics: Aged; Aged, 80 and over; Aging; Antipsychotic Agents; Benzodiazepines; Comorbidity; Female; Geriatri | 1999 |
Reversible leucopenia related to olanzapine.
Topics: Benzodiazepines; Female; Humans; Leukopenia; Male; Middle Aged; Olanzapine; Pirenzepine; Psychotic D | 1999 |
Olanzapine-induced psychotic mania in bipolar schizoaffective disorder.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Female; Humans; Middle Aged; Olanzapine; Pi | 1999 |
Early relapse of psychotic symptoms after an initial response to olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Binding, Competitive; Brief Psychiatric Rating Scale; | 1999 |
Weight gain associated with antipsychotic drugs.
Topics: Administration, Oral; Antipsychotic Agents; Benzodiazepines; Clozapine; Delayed-Action Preparations; | 1999 |
Recurrence of neuroleptic malignant syndrome with olanzapine treatment.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Chlorprothixene; Clopenthixol; Female | 1999 |
Hypomania-like syndrome induced by olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Female; Humans; Olanzapine; Pirenzep | 1999 |
Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Community Mental Health Services; Dose-Resp | 1999 |
[Away from life into a trance. Story of an admission].
Topics: Antipsychotic Agents; Autobiographies as Topic; Benzodiazepines; Commitment of Mentally Ill; Humans; | 2000 |
Olanzapine-induced psychotic mania in bipolar schizo-affective disorder.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Female; Humans; Middle Aged; Olanzapine; Pi | 1999 |
Tardive dyskinesia in older patients.
Topics: Adult; Age Factors; Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiaz | 2000 |
Olanzapine use in the elderly: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Middle Aged; O | 2000 |
Recurrent priapism during treatment with clozapine and olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Interactions; Humans; Male; Olanzapine | 2000 |
Olanzapine and tardive dyskinesia.
Topics: Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Haloperidol; Humans; Olanzapine; Pi | 1999 |
Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Female; Follow-Up St | 2000 |
Olanzapine and weight gain.
Topics: Adult; Benzodiazepines; Female; Humans; Obesity; Olanzapine; Pirenzepine; Psychotic Disorders; Selec | 2000 |
Electroencephalogram alterations during treatment with olanzapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Electroencephalography; Female; Humans; Ma | 2000 |
Esotropia associated with olanzapine.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Depressive Disorder; Esotropia; Female; Humans; O | 2000 |
Remission of tardive dyskinesia after changing from flupenthixol to olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dopamine Antagonists; Dyskinesia, Drug-Induced; Flupen | 2000 |
Diabetes as a result of atypical anti-psychotic drugs--a report of three cases.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Depressive Disorder; Diabetes Mellitus; Gly | 2000 |
Polypharmacy of 2 atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Drug Administrat | 2000 |
Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Chromatography, High Press | 2000 |
Olanzapine-induced neutropenia in patients with history of clozapine treatment: two case reports from a state psychiatric institution.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Drug Administrat | 2000 |
Comparison of cost, dosage and clinical preference for risperidone and olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Drug Utilization; Humans; Israel; Olanzapine; Pirenzepine; Pr | 2000 |
A case of monosymptomatic hypochondriacal psychosis treated with olanzapine.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Female; Humans; Hypochondriasis; Olanzapine; Pirenzepin | 2000 |
[Effective treatment of depressive disorder with psychotic symptoms by olanzapine combination therapy].
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Depressive Disorder | 2000 |
Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationshi | 2000 |
Rapid tranquilization with olanzapine in acute psychosis: a case series.
Topics: Acute Disease; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Drug Administration Sc | 2001 |
Introduction: a new era in the pharmacotherapy of psychotic disorders.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Administration Schedule | 2001 |
Hypothesis and hypothesis testing in the clinical trial.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dibenzothiazepines; Humans; Olanzap | 2001 |
Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the food and drug administration database.
Topics: Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Clinical Trials as Topic; Dat | 2001 |
Olanzapine induces remarkable weight gain in adolescent patients.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanzapine; Pirenzepine; Ps | 2001 |
[Importance of blood glucose level when starting antipsychotic treatment].
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Mid | 2001 |
Olanzapine in pregnancy.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Infant, Newborn; Male; Olanzapine; Pir | 2001 |
Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Drug Administration Schedu | 2001 |
Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Intellectual Disability; M | 2001 |
Olanzapine-induced priapism.
Topics: Adult; Benzodiazepines; Erectile Dysfunction; Humans; Male; Olanzapine; Pirenzepine; Priapism; Psych | 2001 |
Acute, progressive akinetic-rigid syndrome induced by neuroleptics in a case of Wilson's disease.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Hepatolenticular Degeneratio | 2001 |
Body weight gain, insulin, and leptin in olanzapine-treated patients.
Topics: Antipsychotic Agents; Benzodiazepines; Body Weight; Female; Humans; Insulin; Leptin; Male; Metabolic | 2001 |
[Diabetes mellitus induced by olanzapine. A case report].
Topics: Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus; Humans; Male; Middle Aged; Olanzapine; Pir | 2001 |
Olanzapine, new-onset diabetes mellitus, and risk for insulin overdose.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus, Type 1; Dose-Response Relationship, | 2001 |
Are the atypical antipsychotic drugs antidepressants?
Topics: Affect; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Depr | 2002 |
Olanzapine for the treatment of monosymptomatic hypochondriacal psychosis.
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Hypochondriasis; Olanzapine; Pirenzepine; Psychotic D | 2002 |
Eosinophilia associated with olanzapine.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Eosinophilia; Humans; Male; | 2002 |
Olanzapine-induced destabilization of diabetes in the absence of weight gain.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Diabetes Complications; Diabetes | 2002 |
Weight gain and hyperglycaemia associated with olanzapine.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Female; Humans; Hyperglycemia; Olanzapine; Pirenz | 2002 |
Clinical and economic outcomes associated with olanzapine for the treatment of psychotic symptoms in a county mental health population.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; California; Community Mental Health Services; Cost-Ben | 2002 |
One-year rehospitalization rates of patients discharged on atypical versus conventional antipsychotics.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Humans; Middle Aged; Olanzapine; Pat | 2002 |
Decrease of energy expenditure causes weight increase in olanzapine treatment - a case study.
Topics: Antipsychotic Agents; Benzodiazepines; Calorimetry, Indirect; Energy Metabolism; Humans; Male; Middl | 2002 |
Olanzapine and pregnancy.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Olanzapine; Pirenzepine; Pregnancy; Pr | 2002 |